Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 595
interventional 522
Observational 68
Registry 5

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 262
Drug|Other 42
Biological 30
Biological|Drug 19
Drug|Procedure 19
Biological|Drug|Procedure|Radiation 14
Drug|Other|Procedure|Radiation 14
Drug|Procedure|Radiation 13
Biological|Drug|Other|Procedure|Radiation 11
Procedure 10
Biological|Drug|Other 8
Other 8
Biological|Drug|Procedure 7
Biological|Other 6
Biological|Drug|Radiation 5
Device|Drug|Procedure 5
Drug|Genetic|Other 5
Drug|Other|Procedure 5
Drug|Radiation 5
Behavioral 3
Biological|Drug|Other|Procedure 3
Biological|Device|Drug 2
Biological|Other|placebo 2
Combination Product 2
Device 2
Device|Drug 2
Genetic 2
Other|Procedure 2
Biological|Device 1
Biological|Device|Drug|Other 1
Biological|Device|Drug|Radiation 1
Biological|Drug|placebo 1
Biological|Genetic 1
Biological|Genetic|Other|Procedure 1
Biological|Procedure 1
Device|Drug|Procedure|Radiation 1
Diagnostic Test|Other 1
Dietary Supplement|Drug 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|placebo|Procedure 1
Drug|placebo|Procedure 1
Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 302
France 20
Italy 15
China 14
Japan 12
Germany 11
NA 11
United States|Canada 9
Canada 4
United States|Germany|Italy 4
United States|Italy 4
Brazil 3
Israel 3
Korea, Republic of 3
Singapore 3
Spain 3
United Kingdom 3
United States|Australia|Canada 3
Belgium 2
Finland|Norway|Sweden 2
India 2
Malaysia 2
Poland 2
United States|Canada|France|Germany|Hungary|India|Italy|Poland|Singapore|United Kingdom 2
United States|Denmark|Germany 2
United States|France 2
United States|Germany 2
Algeria|Argentina|Australia|Brazil|Canada|Egypt|India|Israel|Lebanon|Malaysia|Mexico|Oman|Russian Federation|Saudi Arabia|South Africa|Taiwan|Thailand|Tunisia|United Arab Emirates 1
Argentina|Australia|Brazil|Canada|France|Spain 1
Argentina|Brazil|China|Colombia|Germany|Guatemala|India|Mexico|Panama|Poland|Russian Federation|Venezuela 1
Australia 1
Australia|Belgium|France|Germany|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|United Kingdom 1
Austria 1
Austria|Belgium|Bulgaria|Croatia|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|Italy|Norway|Poland|Portugal|Romania|Serbia|Slovakia|Slovenia|Spain|Sweden|United Kingdom 1
Austria|Czechia|Italy 1
Belgium|Denmark|France|Germany|Italy|Netherlands|Spain|Sweden|United Kingdom 1
Belgium|Germany 1
Bulgaria|Canada|India|Russian Federation|Slovakia|South Africa|Spain 1
Canada|France 1
Canada|France|Germany|Italy|Spain 1
Canada|Germany|Israel|Italy|Spain 1
Colombia|Venezuela 1
Czechia|Denmark|Finland|France|Germany|Greece|Netherlands|Norway|Portugal|Sweden 1
Czechia|Germany|Switzerland 1
Denmark|Finland|France|Germany|Netherlands|Norway|Sweden 1
Denmark|Finland|Norway|Sweden 1
France|Germany 1
Germany|Netherlands 1
Germany|Switzerland 1
Germany|United Kingdom 1
Germany|United States|Australia|Austria|Belgium|Canada|Denmark|Finland|France|Hong Kong|Italy|Korea, Republic of|Netherlands|New Zealand|Norway|Poland|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
Hong Kong 1
India|Korea, Republic of|Thailand 1
Indonesia|Korea, Republic of|Philippines|Thailand 1
Iran, Islamic Republic of 1
Jordan|Lebanon|Saudi Arabia|Tunisia 1
Korea, Republic of|Turkey|Ukraine 1
Lebanon 1
Mexico 1
New Zealand 1
Peru|United States|Poland|Argentina|Australia|Austria|Belgium|Brazil|Chile|China|Colombia|Czech Republic|Denmark|France|Germany|Greece|Hungary|India|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Russian Federation|Singapore|Spain|Turkey 1
Russian Federation 1
Sweden 1
Switzerland 1
Turkey 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|China|Denmark|Estonia|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Korea, Republic of|Norway|Peru|Philippines|Poland|Puerto Rico|Russian Federation|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czech Republic|Denmark|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Netherlands|Norway|Peru|Philippines|Poland|Russian Federation|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czech Republic|Denmark|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Norway|Peru|Philippines|Poland|Russian Federation|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Peru|Sweden|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Canada|Chile|China|Colombia|Finland|Germany|Hong Kong|Hungary|India|Italy|Korea, Republic of|Mexico|Netherlands|Norway|Peru|Russian Federation|Singapore|South Africa|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|China|Colombia|Finland|France|Hong Kong|Hungary|India|Italy|Japan|Korea, Republic of|Latvia|Netherlands|Peru|Poland|Russian Federation|Singapore|South Africa|Spain|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Peru|Philippines|Singapore|Sweden|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Korea, Republic of|Norway|Peru|Poland|Russian Federation|South Africa|Spain|Sweden|Switzerland|Thailand|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|France|Germany|Greece|Israel|Japan|Korea, Republic of|Mexico|Poland|Russian Federation|Singapore|Spain|Tunisia|United Kingdom 1
United States|Argentina|Australia|Brazil|Bulgaria|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Netherlands|Romania|Russian Federation|Saudi Arabia|Serbia|Spain|Switzerland|Turkey|United Kingdom 1
United States|Argentina|Australia|Canada|Chile|Czechia|Denmark|France|Germany|Hong Kong|Italy|Korea, Republic of|Poland|Portugal|Russian Federation|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Austria|Belgium|Brazil|Canada|China|Czechia|France|Hungary|Italy|Korea, Republic of|Poland|Spain|Thailand 1
United States|Argentina|Austria|Belgium|Brazil|Canada|Colombia|Czechia|Denmark|Egypt|Finland|France|Germany|Hong Kong|Hungary|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Singapore|Slovakia|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|United Kingdom|Venezuela 1
United States|Argentina|Austria|Belgium|Bulgaria|Colombia|Denmark|France|Germany|Greece|Hungary|Ireland|Italy|Japan|Netherlands|Poland|Spain|Sweden|United Kingdom 1
United States|Argentina|Belgium|Brazil|Canada|Chile|China|Colombia|France|Germany|Hong Kong|Hungary|India|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Mexico|Poland|Russian Federation|Singapore|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Ireland|Israel|Italy|Korea, Republic of|Netherlands|Norway|Peru|Singapore|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Philippines|Singapore|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|New Zealand|Norway|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada|Chile|Czechia|Denmark|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Poland|Portugal|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Norway|Poland|Singapore|Slovakia|South Africa|Spain|Sweden|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|Spain 1
United States|Australia|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain 1
United States|Austria|France|Germany|Italy|Norway|Spain|Sweden 1
United States|Belgium 1
United States|Belgium|Czechia|France|Hungary|India|Italy|Korea, Republic of|Romania|Spain|United Kingdom 1
United States|Brazil|France|Israel|Italy|Netherlands|Portugal|Singapore|Spain|United Kingdom 1
United States|Brazil|France|Italy|Korea, Republic of|Netherlands|Russian Federation|United Kingdom 1
United States|Canada|France 1
United States|Canada|France|Germany|Italy|Spain 1
United States|Canada|New Zealand 1
United States|Denmark 1
United States|France|Germany|Italy 1
United States|France|Germany|Italy|Korea, Republic of 1
United States|France|Germany|Italy|Switzerland|United Kingdom 1
United States|France|Germany|Italy|United Kingdom 1
United States|France|Hungary|Italy|Japan|Korea, Republic of|Malaysia|Netherlands|Russian Federation|Spain|Thailand|Turkey|United Kingdom 1
United States|Germany|Ireland|Israel 1
United States|Germany|Israel 1
United States|Hungary|Israel|Italy|Spain 1

Sites per Study

Site_count Study_Count
1 286
2 33
3 24
4 13
5 16
6 6
7 5
8 7
9 10
10 10
11 4
12 8
13 2
14 2
15 3
17 2
18 4
19 2
20 3
21 4
22 5
23 4
24 2
25 4
26 3
27 2
28 2
29 1
30 3
31 1
32 2
34 2
35 2
36 3
38 1
42 1
45 3
50 1
51 2
52 1
53 2
56 1
60 1
62 1
66 1
69 1
70 1
71 1
72 1
73 1
85 1
86 1
97 1
99 2
100 1
101 1
109 1
111 1
112 1
119 1
130 1
131 1
137 1
163 1
166 1
192 1
218 1
233 1
241 1
341 1
454 1

Phase

Phase Study_Count
Phase 2 227
Phase 1 114
Phase 1/Phase 2 66
Phase 3 53
N/A 30
Phase 4 18
Phase 2/Phase 3 10
Early Phase 1 4

Number of Arms

Number_of_Arms Count_of_Studies
1 288
2 109
3 29
4 7
5 5
6 5
7 2
10 1
NA 76

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 6.00 2.00000 3.00000 2.00000 2.0000 9.00 6.0000 18.0000
1st Qu. 16.50 25.50000 19.00000 26.00000 31.7500 27.50 100.0000 46.7500
Median 20.00 54.00000 30.00000 40.00000 60.0000 37.50 226.0000 96.5000
Mean 16.75 97.83333 37.18692 62.26984 88.8785 66.80 350.0588 128.4444
3rd Qu. 20.25 100.00000 44.50000 60.50000 112.0000 87.75 519.0000 124.0000
Max. 21.00 876.00000 330.00000 942.00000 571.0000 245.00 1551.0000 600.0000

Trial Group Type

group_type Group_Count
Experimental 576
NA 76
Active Comparator 65
Other 44
No Intervention 8
Placebo Comparator 5
Sham Comparator 2

Intervention Model

intervention_model Study_Count
Single Group Assignment 339
Parallel Assignment 125
NA 44
Crossover Assignment 11
Sequential Assignment 2
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 470
Supportive Care 21
Prevention 12
Other 7
NA 6
Diagnostic 2
Health Services Research 2
Basic Science 1
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 19
Italy 9
France 8
NA 4
Canada 2
Egypt 2
Germany 2
Israel 2
Korea, Republic of 2
United Kingdom 2
Australia 1
Austria 1
Belgium 1
Canada|Korea, Republic of 1
China 1
France|Germany|Italy|Spain 1
Germany|Hungary|Denmark|Finland|Israel|Poland|Russian Federation|Saudi Arabia|United Kingdom 1
Ireland|United Kingdom 1
Japan 1
Jordan 1
Turkey 1
United States|Australia|Canada|New Zealand|Puerto Rico|Switzerland 1
United States|Austria|Belgium|France|Germany|Greece|Iraq|Italy|Netherlands|Taiwan 1
United States|Austria|Brazil|China|Germany|Iraq|Italy|Malaysia|Netherlands 1
United States|Canada 1
United States|France|Germany|Italy|Netherlands|Puerto Rico|Russian Federation|Spain 1

Sites per Study

Site_count Study_Count
1 38
2 2
3 3
5 1
6 1
7 1
10 2
14 1
16 1
19 2
25 1
26 1
32 2
33 2
37 2
49 1
52 1
56 1
66 2
144 1
192 1
214 1

Enrollment Metrics

Measure Observational
Min 1.000
1st Qu 79.750
Median 126.500
Mean 1757.456
3rd Qu 254.000
Max 99999.000

Observation Model

observational_model Study_Count
Cohort 34
Case-Only 18
Other 8
NA 5
Case-Control 3

Time Perspective

time_perspective Study_Count
Prospective 42
Retrospective 12
Cross-Sectional 7
NA 5
Other 2

Registries

Studies by Country

Country Study_Count
United States 2
Canada 1
Czechia|Germany|Russian Federation|Ukraine 1
Hong Kong 1

Sites per Study

Site_count Study_Count
1 3
7 1
9 1

Enrollment Metrics

Measure Registries
Min 200
1st Qu 250
Median 1000
Mean 1690
3rd Qu 2000
Max 5000

Registry Model

observational_model Study_Count
Case-Only 2
Other 2
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 3
Cross-Sectional 1
Other 1

Follow-up

target_duration Study_Count
1 Year 2
1 Day 1
10 Years 1
5 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03262974 Effect of Pharmacogenetics on Imatinib Plasma Level and Response https://ClinicalTrials.gov/show/NCT03262974 Active, not recruiting Assiut University 2021-05-31
NCT03075969 Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03075969 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2019-03-16
NCT03045120 Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States https://ClinicalTrials.gov/show/NCT03045120 Recruiting Bristol-Myers Squibb 2021-01-31
NCT02977312 Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan https://ClinicalTrials.gov/show/NCT02977312 Completed Hikma Pharmaceuticals LLC 2015-02-28
NCT02896829 Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02896829 Completed University Hospital, Bordeaux 2019-04-30
NCT02895542 Preparatory Work to Assess Adherence to Oral Chemotherapy https://ClinicalTrials.gov/show/NCT02895542 Completed Wake Forest University Health Sciences 2017-04-28
NCT02869256 Regional Central Database Recording of Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT02869256 Recruiting Institut Bergonié 2024-01-31
NCT02767388 Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery https://ClinicalTrials.gov/show/NCT02767388 Completed University of Nebraska 2017-12-11
NCT02734823 Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT02734823 Recruiting University of Southern California 2020-03-01
NCT02733445 Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib https://ClinicalTrials.gov/show/NCT02733445 Completed Bristol-Myers Squibb 2015-12-31
NCT01351545 A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) https://ClinicalTrials.gov/show/NCT01351545 Recruiting Center for International Blood and Marrow Transplant Research 2021-10-31
NCT02546791 Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study https://ClinicalTrials.gov/show/NCT02546791 Completed Bristol-Myers Squibb 2016-11-30
NCT02546375 A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands https://ClinicalTrials.gov/show/NCT02546375 Completed Pfizer 2017-01-16
NCT02501330 Safety And Efficacy Of Bosutinib https://ClinicalTrials.gov/show/NCT02501330 Recruiting Pfizer 2023-09-04
NCT02455024 An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® https://ClinicalTrials.gov/show/NCT02455024 Recruiting Takeda 2020-09-30
NCT02448095 Retrospective Evaluation of CML Patients in the National Compassionate Program https://ClinicalTrials.gov/show/NCT02448095 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT02389972 Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study https://ClinicalTrials.gov/show/NCT02389972 Completed Bristol-Myers Squibb 2017-07-13
NCT02363868 Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population https://ClinicalTrials.gov/show/NCT02363868 Completed Bristol-Myers Squibb 2014-11-30
NCT02348957 Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib https://ClinicalTrials.gov/show/NCT02348957 Completed Onco Medical Consult GmbH 2019-03-31
NCT02338479 Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02338479 Active, not recruiting Center for International Blood and Marrow Transplant Research 2020-02-29
NCT02269267 The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) https://ClinicalTrials.gov/show/NCT02269267 Active, not recruiting Medical College of Wisconsin 2020-09-30
NCT02222272 Effect of 2nd Gen TKI in CML https://ClinicalTrials.gov/show/NCT02222272 Completed European Group for Blood and Marrow Transplantation 2014-03-19
NCT02164903 LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients https://ClinicalTrials.gov/show/NCT02164903 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2017-01-25
NCT02161978 Vascular Dysfunction and Antiangiogenic Therapy https://ClinicalTrials.gov/show/NCT02161978 Completed University Hospital, Angers 2018-12-12
NCT02057185 Occupational Status and Hematological Disease https://ClinicalTrials.gov/show/NCT02057185 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2019-03-31
NCT02016833 Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity https://ClinicalTrials.gov/show/NCT02016833 Completed PX Biosolutions 2014-06-30
NCT01860456 TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study https://ClinicalTrials.gov/show/NCT01860456 Active, not recruiting University of Pisa 2021-05-31
NCT01805843 Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01805843 Completed Medical University of Graz 2015-06-30
NCT01761890 Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib https://ClinicalTrials.gov/show/NCT01761890 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT01752062 Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors https://ClinicalTrials.gov/show/NCT01752062 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT01699217 Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase https://ClinicalTrials.gov/show/NCT01699217 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2019-11-30
NCT01490853 Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy https://ClinicalTrials.gov/show/NCT01490853 Completed Università degli Studi di Brescia 2012-01-31
NCT01475110 Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib https://ClinicalTrials.gov/show/NCT01475110 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT01437202 Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01437202 Completed Asan Medical Center 2012-09-30
NCT01394666 Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) https://ClinicalTrials.gov/show/NCT01394666 Completed Bristol-Myers Squibb 2012-12-31
NCT04150471 Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients https://ClinicalTrials.gov/show/NCT04150471 Recruiting Seoul St. Mary’s Hospital 2020-12-30
NCT04104035 Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response https://ClinicalTrials.gov/show/NCT04104035 Recruiting Ankara University 2021-01-31
NCT04089839 A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting https://ClinicalTrials.gov/show/NCT04089839 Active, not recruiting Bristol-Myers Squibb 2020-10-31
NCT04048564 Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) https://ClinicalTrials.gov/show/NCT04048564 Recruiting Incyte Corporation 2022-02-28
NCT03996096 Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. https://ClinicalTrials.gov/show/NCT03996096 Recruiting University Hospital, Caen 2020-07-31
NCT03933852 Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose https://ClinicalTrials.gov/show/NCT03933852 Recruiting University of Jena 2022-12-31
NCT03885830 Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients https://ClinicalTrials.gov/show/NCT03885830 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2020-12-31
NCT03860376 Ex Vivo Drug Sensitivity Testing and Mutation Profiling https://ClinicalTrials.gov/show/NCT03860376 Recruiting Florida International University 2022-12-15
NCT03678454 Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium https://ClinicalTrials.gov/show/NCT03678454 Recruiting Incyte Corporation 2022-03-31
NCT03540654 Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach https://ClinicalTrials.gov/show/NCT03540654 Completed University Hospital, Bordeaux 2018-10-31
NCT03481868 EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors https://ClinicalTrials.gov/show/NCT03481868 Recruiting University Hospital, Clermont-Ferrand 2021-02-10
NCT03454503 Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt https://ClinicalTrials.gov/show/NCT03454503 Active, not recruiting Hikma Pharmaceuticals LLC 2021-01-31
NCT03421626 Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML) https://ClinicalTrials.gov/show/NCT03421626 Completed Cepheid 2018-08-20
NCT01252589 Patient Reported Outcomes in Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT01252589 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2013-09-30
NCT01244750 Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting https://ClinicalTrials.gov/show/NCT01244750 Active, not recruiting Bristol-Myers Squibb 2020-01-30
NCT01215487 A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib https://ClinicalTrials.gov/show/NCT01215487 Recruiting University of British Columbia 2022-01-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01188278 Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey https://ClinicalTrials.gov/show/NCT01188278 Completed Bristol-Myers Squibb 2013-01-31
NCT01046305 Symptom Burden in Chronic Myeloid Leukemia (CML) https://ClinicalTrials.gov/show/NCT01046305 Active, not recruiting M.D. Anderson Cancer Center 2020-11-30
NCT00947830 Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00947830 Completed McMaster University 2012-04-30
NCT00898755 Collecting and Storing Tissue From Young Patients With Cancer https://ClinicalTrials.gov/show/NCT00898755 Completed Children’s Oncology Group 2008-07-17
NCT00898079 Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer https://ClinicalTrials.gov/show/NCT00898079 Completed Children’s Oncology Group 2018-06-30
NCT00896129 Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy https://ClinicalTrials.gov/show/NCT00896129 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2010-12-31
NCT03647215 CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey https://ClinicalTrials.gov/show/NCT03647215 Recruiting Incyte Corporation 2020-06-30
NCT00816114 Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial https://ClinicalTrials.gov/show/NCT00816114 Recruiting M.D. Anderson Cancer Center 2020-06-30
NCT03709017 Iclusig PMS in CML or Ph+ALL Patients https://ClinicalTrials.gov/show/NCT03709017 Recruiting Korea Otsuka Pharmaceutical Co., Ltd. 2023-06-30
NCT00632255 Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment https://ClinicalTrials.gov/show/NCT00632255 Completed Imperial College London 2009-05-31
NCT00569842 Investigation of the Cylex® ImmuKnow® Assay https://ClinicalTrials.gov/show/NCT00569842 Completed Indiana University 2010-02-28
NCT00513175 Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia https://ClinicalTrials.gov/show/NCT00513175 Completed University of California, San Francisco NA
NCT00429910 Natural History Study of Patients With Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00429910 Completed Dana-Farber Cancer Institute 2005-09-30
NCT00257647 Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) https://ClinicalTrials.gov/show/NCT00257647 Completed Hadassah Medical Organization NA
NCT00159003 Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel https://ClinicalTrials.gov/show/NCT00159003 Completed Hadassah Medical Organization 2017-07-01
NCT00001432 The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00001432 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02760238 Myeloproliferative Neoplasms (MPNs) Patient Registry https://ClinicalTrials.gov/show/NCT02760238 Recruiting University Health Network, Toronto 2025-10-31
NCT01890486 The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen https://ClinicalTrials.gov/show/NCT01890486 Recruiting Wake Forest University Health Sciences 2023-05-31
NCT03869502 European CML Blast Crisis Register https://ClinicalTrials.gov/show/NCT03869502 Recruiting University of Jena 2024-06-30
NCT03625583 The Hong Kong CML Registry https://ClinicalTrials.gov/show/NCT03625583 Recruiting The University of Hong Kong 2023-03-31
NCT04014764 Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy https://ClinicalTrials.gov/show/NCT04014764 Recruiting Notable Labs 2022-09-30